Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-ART-56337
J Med Chem 2018 Sep 13;6117:7486-7502. doi: 10.1021/acs.jmedchem.8b00295.
Show Gene links Show Anatomy links

De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.

Wang Y , Zhao H , Brewer JT , Li H , Lao Y , Amberg W , Behl B , Akritopoulou-Zanze I , Dietrich J , Lange UEW , Pohlki F , Hoft C , Hornberger W , Djuric SW , Sydor J , Mezler M , Relo AL , Vasudevan A .


???displayArticle.abstract???
The development of glycine transporter 1 (GlyT1) inhibitors may offer putative treatments for schizophrenia and other disorders associated with hypofunction of the glutaminergic N-methyl-d-aspartate (NMDA) receptor. Herein, we describe the synthesis and biological evaluation of a series of 3,4-disubstituted pyrrolidine sulfonamides as competitive GlyT1 inhibitors that arose from de novo scaffold design. Relationship of chemical structure to drug-drug interaction (DDI) and bioactivation was mechanistically investigated. Murine studies were strategically incorporated into the screening funnel to provide early assessments of in vivo target occupancy (TO) by ex vivo binding studies. Advanced compounds derived from iterative structure-activity relationship (SAR) studies possessed high potency in ex vivo binding studies and good brain penetration, promising preliminary in vivo efficacy, acceptable preclinical pharmacokinetics, and manageable DDI and bioactivation liabilities.

???displayArticle.pubmedLink??? 29969029
???displayArticle.link??? J Med Chem


Species referenced: Xenopus
Genes referenced: slc6a9